Loading…
Lobbying Spend
—
Filings
771
Firms Hired
18
Active Period
1999–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · third_quarter · Firm: THE NICKLES GROUP, LLC
Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1
Biosimilar Red Tape Elimination Act
2026 · third_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to pharmacy benefit management reforms. Issues related to cardiovascular care. Issues related to drug pricing. Issues related to the drug supply chain. S. 3788, Clear Labels Act. S. 3014, Ensuring Timely Access to Generics Act of 2025; S. 1954, Biosimilar Red Tape Elimination Act; S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1954
Medication Affordability and Patent Integrity Act
2026 · third_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to pharmacy benefit management reforms. Issues related to cardiovascular care. Issues related to drug pricing. Issues related to the drug supply chain. S. 3788, Clear Labels Act. S. 3014, Ensuring Timely Access to Generics Act of 2025; S. 1954, Biosimilar Red Tape Elimination Act; S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 2658
Ensuring Timely Access to Generics Act of 2025
2026 · third_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to pharmacy benefit management reforms. Issues related to cardiovascular care. Issues related to drug pricing. Issues related to the drug supply chain. S. 3788, Clear Labels Act. S. 3014, Ensuring Timely Access to Generics Act of 2025; S. 1954, Biosimilar Red Tape Elimination Act; S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 3014
Issues related to pharmacy benefit management reforms. Issues related to cardiovascular care. Issues related to drug pricing. Issues related to the drug supply chain. S. 3788, Clear Labels Act. S. 3014, Ensuring Timely Access to Generics Act of 2025; S. 1954, Biosimilar Red Tape Elimination Act; S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 3788
Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement under Medicare Part B drugs, including H.R. 4299 -Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
Client expense: — · Firm income: $60,000
Matched citations: H.R. 4299
A resolution designating September 2025 as "National Cholesterol Education Month" and September 30, 2025, as "LDL-C Awareness Day".
2026 · third_quarter · Firm: SIGHTLINE ADVOCACY, LLC
Issues related to drug pricing; Issues related to cardiovascular disease awareness and treatment. S.Res.464 - A resolution designating September 2025 as "National Cholesterol Education Month" and September 30, 2025, as "LDL-C Awareness Day"
Client expense: — · Firm income: $20,000
Matched citations: S.Res.464
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · second_quarter · Firm: THE NICKLES GROUP, LLC
Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1
Biosimilar Red Tape Elimination Act
2026 · second_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to pharmacy benefit management. Issues related to cardiovascular care. Issues related to drug pricing. Issues related to the drug supply chain. S. 3788, Clear Labels Act. S. 3014, Ensuring Timely Access to Generics Act of 2025; S. 1954, Biosimilar Red Tape Elimination Act; S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1954
Medication Affordability and Patent Integrity Act
2026 · second_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to pharmacy benefit management. Issues related to cardiovascular care. Issues related to drug pricing. Issues related to the drug supply chain. S. 3788, Clear Labels Act. S. 3014, Ensuring Timely Access to Generics Act of 2025; S. 1954, Biosimilar Red Tape Elimination Act; S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 2658
Ensuring Timely Access to Generics Act of 2025
2026 · second_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to pharmacy benefit management. Issues related to cardiovascular care. Issues related to drug pricing. Issues related to the drug supply chain. S. 3788, Clear Labels Act. S. 3014, Ensuring Timely Access to Generics Act of 2025; S. 1954, Biosimilar Red Tape Elimination Act; S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 3014
Issues related to pharmacy benefit management. Issues related to cardiovascular care. Issues related to drug pricing. Issues related to the drug supply chain. S. 3788, Clear Labels Act. S. 3014, Ensuring Timely Access to Generics Act of 2025; S. 1954, Biosimilar Red Tape Elimination Act; S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 3788
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · first_quarter · Firm: THE NICKLES GROUP, LLC
Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1
Issues related to pharmacy benefit management. Issues related to cardiovascular care. Issues related to drug pricing. Issues related to the drug supply chain. S. 3788, Clear Labels Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 3788
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Monitored issues related to cardiovascular health. Issues related to pharmacy benefit management. Monitored issues related to dialysis services. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to pharmacy benefit management and drug pricing policies. Issues related to the Most Favored Nation drug pricing.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1
Methane Waste Prevention Act of 2021
2025 · fourth_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement under Medicare Part B drugs. Support for H.R. 1492/S. 839, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1492
Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement under Medicare Part B drugs. Support for H.R. 1492/S. 839, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model
Client expense: — · Firm income: $60,000
Matched citations: S. 839
Biosimilar Red Tape Elimination Act
2025 · fourth_quarter · Firm: SIGHTLINE ADVOCACY, LLC
Issues related to drug pricing; H.R. 5526 - Biosimilar Red Tape Elimination Act
Client expense: — · Firm income: $20,000
Matched citations: H.R. 5526
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · third_quarter · Firm: THE NICKLES GROUP, LLC
H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · third_quarter · Firm: THE NICKLES GROUP, LLC
Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Monitored issues related to cardiovascular health. Issues related to pharmacy benefit management. Monitored issues related to dialysis services. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to pharmacy benefit management and drug pricing policies. H.R. 946 / S. 1862, ORPHAN Cures Act. Issues related to the Most Favored Nation drug pricing.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1
Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Monitored issues related to cardiovascular health. Issues related to pharmacy benefit management. Monitored issues related to dialysis services. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to pharmacy benefit management and drug pricing policies. H.R. 946 / S. 1862, ORPHAN Cures Act. Issues related to the Most Favored Nation drug pricing.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 946
Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Monitored issues related to cardiovascular health. Issues related to pharmacy benefit management. Monitored issues related to dialysis services. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to pharmacy benefit management and drug pricing policies. H.R. 946 / S. 1862, ORPHAN Cures Act. Issues related to the Most Favored Nation drug pricing.
Client expense: — · Firm income: $60,000
Matched citations: S. 1862
Methane Waste Prevention Act of 2021
2025 · third_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement under Medicare Part B drugs. Support for H.R. 1492/S. 839, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1492
Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement under Medicare Part B drugs. Support for H.R. 1492/S. 839, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model
Client expense: — · Firm income: $60,000
Matched citations: S. 839
Source: Senate LDA